DUBLIN, March 15, 2024 /PRNewswire/ — The “HIV Point of Care (POC) Tests Pipeline by Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies” report has been added to ResearchAndMarkets.com’s offering.
The report provides comprehensive information about the HIV Point of care (POC) Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
HIV Point of care (POC) Tests is defined as medical diagnostic testing performed outside the clinical laboratory in close proximity to where the patient is receiving care. POC is typically performed by non-laboratory personnel and the results are used for clinical decision making. POC has a range of complexity and procedures that vary from manual methodologies to automated analyzers. POC devices are often ‘handheld’ or may be small portable analyzers.
Scope
- Extensive coverage of the HIV Point of care (POC) Tests under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of HIV Point of care (POC) Tests and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
- Identify and understand important and diverse types of HIV Point of care (POC) Tests under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Key Topics Covered:
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 HIV Point of care (POC) Tests Overview
3 Products under Development
3.1 HIV Point of care (POC) Tests – Pipeline Products by Stage of Development
3.2 HIV Point of care (POC) Tests – Pipeline Products by Territory
3.3 HIV Point of care (POC) Tests – Pipeline Products by Regulatory Path
3.4 HIV Point of care (POC) Tests – Pipeline Products by Estimated Approval Date
3.5 HIV Point of care (POC) Tests – Ongoing Clinical Trials
4 HIV Point of care (POC) Tests – Pipeline Products under Development by Companies
4.1 HIV Point of care (POC) Tests Companies – Pipeline Products by Stage of Development
4.2 HIV Point of care (POC) Tests – Pipeline Products by Stage of Development
5 HIV Point of care (POC) Tests Companies and Product Overview
6 HIV Point of care (POC) Tests- Recent Developments
6.1 Oct 10, 2023: Trinity Biotech Welcomes the Decision of the High Court of Kenya to Strike Out the Applications to Prevent the Procurement of Trinscreen HIV by the Kenyan Ministry of Health
6.2 Sep 27, 2023: Update on MedMira’s Regulatory Path in Canada and the USA
6.3 Jun 14, 2023: Atomo and Newfoundland Sign Agreement for HIV Testing in Europe
6.4 Mar 22, 2023: Trinity Biotech welcomes TrinScreen HIV’s inclusion in the New Kenyan HIV Testing Algorithm
6.5 Feb 28, 2023: Significant purchase order for HIV self-tests for Europe
7 Appendix
A selection of companies mentioned in this report includes
- Abbott Rapid Diagnostics GmbH
- Aldatu Biosciences Inc
- Altratech Ltd
- Atomo Diagnostics Ltd
- Baebies Inc
- BBB Technologies Inc
- Beijing Wantai Biological Pharmacy Enterprise Co Ltd
- Binx Health Inc
- Bio-AMD Inc
- Biocartis Group NV
- BioHelix Corp
- Bluejay Diagnostics Inc
- Calypte Biomedical Corporation
- Centre International de Reference Chantal Biya
- Cepheid Inc
- ChipCare Corp
- CrossLife Technologies Inc
- Cue Inc
- Daktari Diagnostics, Inc.
- Diagnostics For All Inc
- Diagnostics for the Real World (Europe) Ltd
- Endeavor Sciences Inc
- Epinex Diagnostics Inc
- ERBA Molecular Ltd
- Fluxergy LLC
- GAIA Medical Institute LLC
- genedrive plc
- Group K Diagnostics
- Guangzhou Wondfo Biotech Co Ltd
- HA TECH Pty Ltd
- HeatFlow Technologies Inc
- Identifysensors LLC
- Imperial College London
- Integrated Diagnostics Inc (Inactive)
- Intuitive Biosciences Inc
- Jan Biotech Inc
- Jinvator Bio Med GmbH
- Johns Hopkins University
- Lynntech Inc
- Maxim Biomedical Inc
- MedMira Inc
- Micronics Inc
- Molbio Diagnostics Pvt Ltd
- MyMD Pharmaceuticals Inc
- Nanobiosym Inc
- Newmark Diagnostics LLC
- Northwestern University
- Osel Inc
- Philmedi Co Ltd
- Prenetics Ltd
- QuantuMDx Group Ltd
- Quidel Corp
- Radisens Diagnostics Ltd
- Rheonix Inc
- Roche Diagnostics International Ltd
- Sedia Biosciences Corp
- Sensible Diagnostics Inc
- Senzo Inc
- TheoremDx Inc
- Trinity Biotech Plc
- University of Connecticut
- University of Minnesota
- UrSure Inc
- Ustar Biotechnologies (Hangzhou) Ltd.
- Virax Biolabs Group Ltd
- Wave 80 Biosciences Inc
- Yaathum Biotech Pvt Ltd
For more information about this report visit https://www.researchandmarkets.com/r/w2cr75
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets
